Mouse-adapted SARS-CoV-2 protects animals from lethal SARS-CoV challenge

PLoS Biol. 2021 Nov 4;19(11):e3001284. doi: 10.1371/journal.pbio.3001284. eCollection 2021 Nov.

Abstract

The emergence of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has resulted in a pandemic causing significant damage to public health and the economy. Efforts to understand the mechanisms of Coronavirus Disease 2019 (COVID-19) have been hampered by the lack of robust mouse models. To overcome this barrier, we used a reverse genetic system to generate a mouse-adapted strain of SARS-CoV-2. Incorporating key mutations found in SARS-CoV-2 variants, this model recapitulates critical elements of human infection including viral replication in the lung, immune cell infiltration, and significant in vivo disease. Importantly, mouse adaptation of SARS-CoV-2 does not impair replication in human airway cells and maintains antigenicity similar to human SARS-CoV-2 strains. Coupled with the incorporation of mutations found in variants of concern, CMA3p20 offers several advantages over other mouse-adapted SARS-CoV-2 strains. Using this model, we demonstrate that SARS-CoV-2-infected mice are protected from lethal challenge with the original Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV), suggesting immunity from heterologous Coronavirus (CoV) strains. Together, the results highlight the use of this mouse model for further study of SARS-CoV-2 infection and disease.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • COVID-19 / pathology
  • COVID-19 / prevention & control*
  • COVID-19 Vaccines / immunology*
  • COVID-19 Vaccines / therapeutic use
  • Cell Line
  • Disease Models, Animal
  • Female
  • Humans
  • Lung / pathology
  • Mice
  • Mice, Inbred BALB C
  • Reverse Genetics
  • SARS-CoV-2 / immunology*
  • Serial Passage
  • Virus Replication

Substances

  • COVID-19 Vaccines